Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

NCT ID: NCT05518123

Last Updated: 2025-07-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

658 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-07

Study Completion Date

2025-07-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Migraine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rimegepant 75 mg

Group Type EXPERIMENTAL

Rimegepant

Intervention Type DRUG

Rimegepant 75 mg Oral Disintegrating Tablet (ODT) taken every other day during Double-blind Treatment (DBT) phase

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching placebo with every other day dosing during DBT phase

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rimegepant

Rimegepant 75 mg Oral Disintegrating Tablet (ODT) taken every other day during Double-blind Treatment (DBT) phase

Intervention Type DRUG

Placebo

Matching placebo with every other day dosing during DBT phase

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Migraine attacks present for more than 1 year with the age of onset prior to 50 years of age.
2. Migraine attacks, on average, lasting about 4 - 72 hours, if untreated.
3. 4 to 14 migraine days per month, on average, across the 3 months prior to the Screening Visit (month is defined as 28-days for the purpose of this protocol).
4. Less than15 headache days (migraine or non-migraine) per month in each of the 3-months prior to the Screening Visit and throughout the Screening Phase.
5. Subjects must be able to distinguish migraine attacks from tension/cluster headaches. Prior inadequate response, within 10 years of the Screening Visit, to agents across 2-4 categories of recognized, orally-administered, migraine-preventive medications where at least one example of prior inadequate response is due to lack of efficacy or prior intolerance (not contraindication).

Exclusion Criteria

1. History of cluster headaches, basilar migraine (migraine with brainstem aura), or hemiplegic migraine.
2. Current medication overuse headaches.
3. 15 or more headache days (migraine or non-migraine) per month in any of the 3-months prior to the Screening Visit or during the first 28- days of the Observation Phase.
4. Inadequate response (due to lack of efficacy, prior intolerance, or contraindication) to agents across \> 4 categories of recognized, orally administered, migraine-preventive medications.
5. Active chronic pain syndrome (such as fibromyalgia, chronic pelvic pain, complex regional pain syndrome \[CRPS\]).
6. Other pain syndromes (including trigeminal neuralgia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, interfere with study assessments of safety or efficacy.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Research Institute

Los Angeles, California, United States

Site Status

California Neuroscience Research, LLC

Sherman Oaks, California, United States

Site Status

Ki Health Partners LLC, dba New England Institute for Clinical Research

Stamford, Connecticut, United States

Site Status

Sandhill Research, LLC d/b/a Accel Research Sites Network-Edgewater Clinical Research Unit

Edgewater, Florida, United States

Site Status

Wr-Msra,Llc

Lake City, Florida, United States

Site Status

AppleMed Research Group, LLC

Miami, Florida, United States

Site Status

Sensible Healthcare LLC

Ocoee, Florida, United States

Site Status

Sandhill Research, LLC d/b/a Accel Research Sites Network - Ormond Clinical Research Unit

Ormond Beach, Florida, United States

Site Status

Boston Clinical Trials

Boston, Massachusetts, United States

Site Status

Community Clinical Research Network, Inc.

Marlborough, Massachusetts, United States

Site Status

Michigan Headache & Neurological Institute

Ann Arbor, Michigan, United States

Site Status

Rochester Medical Group

Rochester Hills, Michigan, United States

Site Status

Clinvest Research, LLC

Springfield, Missouri, United States

Site Status

St Charles Clinical Research

Weldon Spring, Missouri, United States

Site Status

Wr-Crcn, Llc

Las Vegas, Nevada, United States

Site Status

Albuquerque Clinical Trials. Inc.

Albuquerque, New Mexico, United States

Site Status

DiGiovanna Institute for Medical Education And Research

North Massapequa, New York, United States

Site Status

Headache Wellness Center, PC

Greensboro, North Carolina, United States

Site Status

Synexus Clinical Research US, Inc. - Anderson

Anderson, South Carolina, United States

Site Status

Alliance for Multispecialty Reseach, LLC

Knoxville, Tennessee, United States

Site Status

Red Star Research, LLC

Lake Jackson, Texas, United States

Site Status

DM Clinical Research

Tomball, Texas, United States

Site Status

Northwest Clinical Research Center

Bellevue, Washington, United States

Site Status

USC Clinical Trials Sunshine Coast

Sippy Downs, Queensland, Australia

Site Status

Medical University Innsbruck

Innsbruck, Tyrol, Austria

Site Status

Klinikum Klagenfurt am Wörthersee

Klagenfurt, , Austria

Site Status

UZ Brussel

Jette, Brussels Capital, Belgium

Site Status

GZA Ziekenhuizen

Antwerp, , Belgium

Site Status

AZ Sint-Jan Brugge-Oostende AV

Bruges, , Belgium

Site Status

Jessa Ziekenhuis

Hasselt, , Belgium

Site Status

Clinique de la Citadelle

Liège, , Belgium

Site Status

Cabinet Privé Dr. Simona Sava

Saint Nicolas Province de Liège, , Belgium

Site Status

Aggarwal and Associates Limited

Brampton, Ontario, Canada

Site Status

NeuPath Centre for Pain and Spine

Brampton, Ontario, Canada

Site Status

Centre de Recherche Saint-Louis/Clinique Neuro-Levis

Lévis, Quebec, Canada

Site Status

ALPHA Recherche Clinique

Québec, Quebec, Canada

Site Status

ALPHA Recherche Clinique

Québec, , Canada

Site Status

Bispebjerg Hospital

Copenhagen NV, Capital Region, Denmark

Site Status

Danish Headache Center

Glostrup Municipality, Capital Region, Denmark

Site Status

University Hospital of Southern Denmark

Esbjerg, , Denmark

Site Status

Hospitalsenhed Midt

Viborg, , Denmark

Site Status

Terveystalo Ruoholahti

Helsinki, Uusimaa, Finland

Site Status

Terveystalo Tampere

Tampere, , Finland

Site Status

Terveystalo Pulssi

Turku, , Finland

Site Status

Schmerz- und Palliativzentrum Göppingen

Göppingen, Baden-Wurttemberg, Germany

Site Status

Zentrum für klinische Forschung

Bad Homburg, Hesse, Germany

Site Status

Synexus Clinical Research GmbH Synexus Frankfurt Clinical Research Centre

Frankfurt am Main, Hesse, Germany

Site Status

Kopfschmerzzentrum Frankfurt

Frankfurt am Main, Hesse, Germany

Site Status

Intermed GmbH

Wiesbaden, Hesse, Germany

Site Status

Studienzentrum Nordwest

Westerstede, Lower Saxony, Germany

Site Status

Synexus - Prüfzentrum Leipzig

Leipzig, Saxony, Germany

Site Status

Synexus - Prüfzentrum Berlin

Berlin, , Germany

Site Status

Neuropoint GmbH

Ulm Baden-Wuerttemberg, , Germany

Site Status

IRCCS Fondazione Istituto Neurologico Nazionale C. Mondino

Pavia, Lombardy, Italy

Site Status

IRCCS Ospedale San Raffaele

Milan, MI, Italy

Site Status

AOU Luigi Vanvitelli

Napoli, Naples, Italy

Site Status

IRCCS San Raffaele

Rome, Rome/lazio, Italy

Site Status

SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi

Florence, , Italy

Site Status

IRCCS Fondazione Besta

Milan, , Italy

Site Status

University Modena e Reggio Emilia

Modena, , Italy

Site Status

Phylasis Clinicas Research S. de R.L. de C.V.

Cuautitlán Izcalli, State of Mexico, Mexico

Site Status

Clinical Research Institute S.C.

Tlalnepantla, State of Mexico, Mexico

Site Status

Medical Care and Research S.A. de C.V.

Mérida, Yucatán, Mexico

Site Status

Centro de Investigación Médica de Aguascalientes (CIMA)

Aguascalientes, , Mexico

Site Status

Clinstile, SA de CV

Mexico City, , Mexico

Site Status

Operadora Unidad de Investigación En Salud de Chihuahua, Sa de Cv

Mexico City, , Mexico

Site Status

Centrum Medyczne Neuromed

Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

Site Status

MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak

Wroclaw, Lower Silesian Voivodeship, Poland

Site Status

Twoja Przychodnia Nowosolskie Centrum Medyczne

Nowa Sól, Lubusz Voivodeship, Poland

Site Status

Centermed Kraków Sp. Z o.o.

Krakow, Malopolska, Poland

Site Status

Concept Medica

Warsaw, Masovian Voivodeship, Poland

Site Status

Dr Sekowska Leczenie Bolu

Warsaw, Masovian Voivodeship, Poland

Site Status

MICS Centrum Medyczne Damiana Walbrzyska

Warsaw, Masovian Voivodeship, Poland

Site Status

Instytut Zdrowia

Oświęcim, Małopolska, Poland

Site Status

Centrum Medyczne Pratia Katowice

Katowice, , Poland

Site Status

Vita Longa Sp. Z o.o.

Katowice, , Poland

Site Status

MICS Centrum Medyczne Szczecin

Szczecin, , Poland

Site Status

MTZ Clinical Research Powered by Pratia

Warsaw, , Poland

Site Status

Premium Clinic Wrocław

Wroclaw, , Poland

Site Status

Centrum Medyczne OPOROW

Wroclaw, , Poland

Site Status

Centrum Leczenia Bolu dr n med Lukasz Kmieciak

Lodz, Łódź Voivodeship, Poland

Site Status

Hospital Universitario de Elda

Elda, Alicante, Spain

Site Status

Hospital Clinic de Barcelona Plato Headquarters

Barcelona, , Spain

Site Status

Hospital Universitario Vall d'Hebron

Barcelona, , Spain

Site Status

Hospital Universitario de La Princesa

Madrid, , Spain

Site Status

Hospital Universitario Fundacion Jimenez Diaz

Madrid, , Spain

Site Status

Hospital Universitario La Paz

Madrid, , Spain

Site Status

Hospital Universitario HM Sanchinarro

Madrid, , Spain

Site Status

Hospital Universitario Ruber Juan Bravo

Salamanca, , Spain

Site Status

University Hospital Marqués de Valdecilla

Santander, , Spain

Site Status

Hospital Universitario Virgen Macarena

Seville, , Spain

Site Status

Virgen del Rocio University Hospital

Seville, , Spain

Site Status

Hospital Clínico Universitario de Valencia

Valencia, , Spain

Site Status

Consorcio Hospital General Universitario

Valencia, , Spain

Site Status

Hospital Clinico Universitario de Valladolid

Valladolid, , Spain

Site Status

CTC Solna

Solna, Stockholms LÄN [se-01], Sweden

Site Status

CTC MTC

Uppsala, Uppsala LÄN [se-03], Sweden

Site Status

Carlanderska Hospital

Gothenburg, , Sweden

Site Status

Skåneuro Privatmottagning

Lund, , Sweden

Site Status

Hälsoklustret

Stockholm, , Sweden

Site Status

Akardo Med Site

Stockholm, , Sweden

Site Status

University Hospital Uppsala (VO Neuro)

Uppsala, , Sweden

Site Status

Re: Cognition Health Ltd.

Edgebaston, Birmingham, United Kingdom

Site Status

Hull University Hospitals NHS Trust

Hull, EAST Riding, United Kingdom

Site Status

4 Medical Clinical Solutions London

Ilford, Essex, United Kingdom

Site Status

James Paget University Hospitals NHS Foundation Trust

Great Yarmouth, Norfolk, United Kingdom

Site Status

Lakeside Healthcare Group Research

Corby, Northamptonshire, United Kingdom

Site Status

Queen Elizabeth University Hospital

Glasgow, Scotland, United Kingdom

Site Status

Cognition Health - Bristol

Bristol, , United Kingdom

Site Status

Kings College London

London, , United Kingdom

Site Status

4 Medical Clinical Solutions

Swinton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belgium Canada Denmark Finland Germany Italy Mexico Poland Spain Sweden United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

https://pmiform.com/clinical-trial-info-request?StudyID=BHV3000-407

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C4951012

Identifier Type: OTHER

Identifier Source: secondary_id

BHV3000-407

Identifier Type: REGISTRY

Identifier Source: secondary_id

2022-001176-34

Identifier Type: REGISTRY

Identifier Source: secondary_id

2024-513270-21-00

Identifier Type: REGISTRY

Identifier Source: secondary_id

BHV3000-407

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.